Similarly, earlier reports have indicated molecular evidence linking disruptions of the molecular machinery of the circadian system to cancers, including lung cancer, hepatocellular carcinoma, lymphoma, glioma, and HER2-positive advanced gastric cancer (3, 6). This evidence concerns the gene ERBB2 and cancer.